MRVI vs STAA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRVI presents a contradictory profile characterized by a stable Piotroski F-Score of 4/9 and exceptional short-term liquidity (Current Ratio 6.60), yet plagued by severe long-term value destruction (-91% 5Y change). While the company is showing signs of an earnings bottom with a 77.8% YoY EPS improvement, the fundamental top-line growth is negative (-11.8% YoY), suggesting the recovery is driven by cost-cutting rather than market expansion. The stock is currently in a technical recovery phase (85.3% 1Y return) but remains fundamentally fragile due to negative profit margins of -70.41%.
STAA exhibits severe fundamental weakness as evidenced by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position (Current Ratio 4.55) and impressive gross margins (76.19%), it is unable to translate revenue growth into profitability, with a profit margin of -33.60%. The stock is currently trading at $25.08, which is a premium to the analyst target price of $21.11. Despite a favorable PEG ratio of 0.76, the lack of earnings stability and a bearish technical trend outweigh the growth potential.
Compare Another Pair
Related Comparisons
MRVI vs STAA: Head-to-Head Comparison
This page compares Maravai LifeSciences Holdings, Inc. (MRVI) and STAAR Surgical Company (STAA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.